Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Form 8-K Summary

Reporting date: November 19, 2020, filed November 23, 2020. The provided filing identifies the registrant as Galecto, Inc. (Nasdaq: GLTO), although the request metadata names Damora Therapeutics, Inc.

Business Context and Reporting Period

This current report concerns a board appointment and amendments to the company’s non-employee director compensation policy. It does not report quarterly or annual financial results.

Financial Metrics and Liquidity

  • The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating performance metrics.
  • No financial statements are included or reported in the provided text.

Material Changes

  • The board increased its size to eight directors and appointed Dr. Jayson Dallas as an independent Class III director, effective November 19, 2020.
  • Dr. Dallas is expected to stand for election at the 2023 annual meeting and was appointed to the Nominating and Corporate Governance Committee.
  • The Nominating and Corporate Governance Committee now consists of Dr. Dallas, Chau Q. Khuong, and Søren Møller. The Audit and Compensation Committee compositions were unchanged.
  • The company amended its Non-Employee Director Compensation Policy. New directors appointed outside the annual meeting date may receive a prorated annual option award covering 18,000 common shares, with monthly vesting over the following 12 months.
  • Directors who joined before the initial public offering but did not receive a 2020 equity award may be eligible for an annual award in 2021.

Compensation, Outlook, and Risks

  • Dr. Dallas will receive cash compensation and equity awards under the amended non-employee director policy, including an initial grant and a prorated 2020 annual grant.
  • The filing does not provide business guidance, financial outlook, material risks, contingencies, or unusual operating items.
  • Dr. Dallas entered into a customary indemnification agreement and was not party to any related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.

Investor Verification Items

  • Verify the registrant’s identity, because the filing text names Galecto, Inc., while the request metadata names Damora Therapeutics, Inc.
  • Review Exhibit 10.1 for the complete director compensation policy and award terms.
  • Review Exhibit 99.1 for the November 23, 2020 press release regarding Dr. Dallas’s appointment.
  • Confirm the final option grant size and prorated vesting schedule applicable to Dr. Dallas.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.